Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124512422 | 12451242 | 2 | F | 201512 | 20160617 | 20160609 | 20160701 | PER | US-PFIZER INC-2016278320 | PFIZER | 47.00 | YR | F | Y | 0.00000 | 20160701 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124512422 | 12451242 | 1 | PS | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | UNK | Y | 20699 | ||||||||||
| 124512422 | 12451242 | 2 | C | LAMOTRIGINE. | LAMOTRIGINE | 1 | UNK | 0 | |||||||||||
| 124512422 | 12451242 | 3 | C | LISINOPRIL. | LISINOPRIL | 1 | UNK | 0 | |||||||||||
| 124512422 | 12451242 | 4 | C | ATORVASTATIN | ATORVASTATIN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124512422 | 12451242 | 1 | Depression |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124512422 | 12451242 | Tinnitus | |
| 124512422 | 12451242 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124512422 | 12451242 | 1 | 201512 | 201605 | 0 | |
| 124512422 | 12451242 | 2 | 2013 | 0 | ||
| 124512422 | 12451242 | 3 | 2010 | 0 | ||
| 124512422 | 12451242 | 4 | 2011 | 0 |